Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antibiotic OTC in UK

This article was originally published in The Tan Sheet

Executive Summary

Nottingham-based Optrex is launching Optrex Infected Eyes Eye Drops, the first nonprescription antibiotic eye drop for the treatment of conjunctivitis, expected to appear on UK pharmacy shelves by the end of June. Britain's Medicines & Healthcare products Regulatory Agency approved chloramphenicol 0.5 % eye drops for the treatment of acute bacterial conjunctivitis in adults and children aged two and older for pharmacy sale June 8. MHRA says it has weighed safety and bacterial resistance risks and is "convinced that the potential health benefits outweigh any risks to patients or to the community at large." Boots Pharmacy also will offer a private-label equivalent, according to MHRA...

You may also be interested in...

Antibiotic eye drops study

"Healthy children with acute conjunctivitis do not need an ocular antibiotic at first presentation to primary care," Peter Rose, MD, Department of Primary Health Care, University of Oxford, et al., find in a study published in The Lancet. The randomized, double-blind trial compared the effects of chloramphenicol eye drops to placebo in 326 children age 6 months to 12 years. Clinical cure of eye infection occurred by day seven in 83% of children in the placebo group and 86% of those treated with the antibiotic, the authors state. Rose et al. advise forgoing medical consultation unless the child's symptoms are "unusual" or persist for more than a week. The UK's Medicines & Healthcare products Regulatory Agency approved chloramphenicol 0.5% for pharmacy sale in June (1"The Tan Sheet" June 13, 2005, In Brief)...

Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race

Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.

Brazil Authorizes Oxford/AZ and Sinovac Vaccines

In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts